Corcept Therapeutics (HAM:HTD) Other Current Receivables: €0.0 Mil (As of Mar. 2026)


HAM:HTD Corcept Therapeutics Inc HAM:HTD
85 GF Score
Price €77.70
GF Value €53.65
! 8 Warning Signs
View Full Analysis

What is Corcept Therapeutics Other Current Receivables?

Corcept Therapeutics HAM:HTD +3.85% 85 Other Current Receivables is €0.0 Mil as of Mar. 2026. GuruFocus rates HAM:HTD with a GF Score™ of 85/100 and a GF Value™ of €53.65. The stock has 8 warning signs investors should review.

Corcept Therapeutics's Other Current Receivables for the quarter that ended in Mar. 2026 was €0.0 Mil.

Corcept Therapeutics's annual Other Current Receivables declined from Dec. 2023 (€12.84 Mil) to Dec. 2024 (€0.00 Mil) but then stayed the same from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Corcept Therapeutics Other Current Receivables Related Terms

Corcept Therapeutics Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Corcept Therapeutics's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics Other Current Receivables Chart

Corcept Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 13.22 12.84 0.00 0.00

Corcept Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HAM:HTD
85GF Score
Corcept Therapeutics Inc HAM:HTD
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corcept Therapeutics Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €0.0 Mil mean?
Corcept Therapeutics (HAM:HTD) has a Other Current Receivables of €0.0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Corcept Therapeutics and its competitors.
Is Corcept Therapeutics' Other Current Receivables too high?
Corcept Therapeutics' current Other Current Receivables is €0.0 Mil. Overall, Corcept Therapeutics has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Corcept Therapeutics' Other Current Receivables compare to PRAX and IBRX?
Corcept Therapeutics' Other Current Receivables of €0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Corcept Therapeutics and its competitors. Corcept Therapeutics's current Other Current Receivables is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corcept Therapeutics stock overvalued right now?
Corcept Therapeutics (HAM:HTD) has a current Other Current Receivables of €0.0 Mil. The stock's GF Value™ is €53.65, compared to a current price of €77.70 — trading 44.8% above its estimated fair value. The current Other Current Receivables is €0.0 Mil. Corcept Therapeutics' overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Corcept Therapeutics (HAM:HTD), the current Other Current Receivables is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Corcept Therapeutics (HAM:HTD) Overvalued in 2026?

Based on GuruFocus' analysis, Corcept Therapeutics stock appears to be overvalued. The current stock price of €77.70 is trading 44.8% above its estimated GF Value™ of €53.65.

Key valuation signals for HAM:HTD:

  • Other Current Receivables: €0.0 Mil
  • GF Value™: €53.65 vs. price of €77.70 (44.8% above fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the HAM:HTD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Corcept Therapeutics Business Description

Address 101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
85GF Score

Get the complete analysis for HAM:HTD

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.70
Price
€53.65
GF Value